Filing Flows › Jazz Pharmaceuticals (JAZZ) › Rylaze/Enrylaze revenue
Jazz Pharmaceuticals (JAZZ) Rylaze/Enrylaze revenue by quarter
Jazz Pharmaceuticals' Rylaze/Enrylaze revenue was $106M in Q3 2026 (third quarter 2026), +7% from Q2 2026. Over the last 7 quarters it ranged from $94.2M (Q1 2025) to $108M (Q4 2025).
| Quarter | Rylaze/Enrylaze revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $106M | +7% | +6% |
| Q2 2026 | $99.5M | -4% | -1% |
| Q1 2026 | $104M | -4% | +10% |
| Q4 2025 | $108M | +8% | — |
| Q3 2025 | $99.9M | -0.8% | — |
| Q2 2025 | $101M | +7% | — |
| Q1 2025 | $94.2M | — | — |
Q3 2026 at a glance
Jazz Pharmaceuticals, Q3 2026: revenue $1.2B (+10% year over year), operating margin -33.3%, net loss $483M, operating cash flow $506M. The chart follows the revenue to costs, profit and cash.
Questions
What is Jazz Pharmaceuticals' Rylaze/Enrylaze revenue?
Jazz Pharmaceuticals' Rylaze/Enrylaze revenue was $106M in Q3 2026 (third quarter 2026), +7% from Q2 2026.
How has Jazz Pharmaceuticals' Rylaze/Enrylaze revenue changed?
Over the last 7 quarters it ranged from $94.2M (Q1 2025) to $108M (Q4 2025).